explore -WSS

explore

author：entertainment 2025-09-27 09:46:09 - browse：96

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

leisure time

WSS

Anthos stroke drug appears safer than common blood thinner

World's first CRISPR

Hospitals look to new technology to keep health care workers safe

Health care needs a new profession: neuroimaging counseling

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Orangutan used medicinal plant to treat wound, first time ever seen

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Key Senate committee drafts bipartisan bill to stem drug shortages

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ransomware attacks on hospitals: Study outlines patient impact

Jerome Adams on the need for new antivirals for Covid

Poor hospice wound care hurts patients and families

Alkermes shareholders re

Melinda French Gates resigns from Gates Foundation

Sports medicine is finally prioritizing gender equality

Orangutan used medicinal plant to treat wound, first time ever seen

entertainment

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout LOUD podcast: A CRISPR milestone, biotech mixology

FDA's Woodcock to retire early next year

Cholera vaccine supply gets boost as demand surges globally

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Q&A: Jennifer Adair on making gene therapy available globally

leisure time

explore

leisure time

focus